Abiopharma

Revvity - Revvity Announces Financial Results for the Second Quarter of 2025

Serina Therapeutics to Present at the BTIG Virtual Biotechnology Conference

Revvity Announces Financial Results for the Second Quarter of 2025

Theravance Biopharma to Report Second Quarter 2025 Financial Results on August 12, 2025

Zevra Therapeutics Submits Marketing Authorization Application to European Medicines Agency to Review Arimoclomol for the Treatment of Niemann-Pick Disease Type C

Zymeworks Announces FDA Clearance of Investigational New Drug Application for ZW251, a Novel Glypican 3-Targeted Topoisomerase 1 Inhibitor Antibody-Drug Conjugate

General Announcement: CHANGES IN SUBSTANTIAL SHAREHOLDERS INTEREST PURSUANT TO SECTION 138 OF THE COMPANIES ACT 2016

So-Young to Report Second Quarter 2025 Financial Results on August 15, 2025

FDA approve CEFPROZIL

FDA approve EXEMESTANE

FDA approve EXEMESTANE

FDA approve EXEMESTANE

FDA approve FAMOTIDINE

FDA approve DEXTROSE

FDA approve CEVIMELINE HYDROCHLORIDE